A detailed history of Ubs Oconnor LLC transactions in Insmed Inc stock. As of the latest transaction made, Ubs Oconnor LLC holds 18,000 shares of INSM stock, worth $1.41 Million. This represents 0.09% of its overall portfolio holdings.

Number of Shares
18,000
Holding current value
$1.41 Million
% of portfolio
0.09%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$62.0 - $79.01 $474,300 - $604,426
7,650 Added 53.99%
21,819 $1.59 Million
Q2 2024

Aug 14, 2024

SELL
$22.0 - $69.71 $865,436 - $2.74 Million
-39,338 Reduced 73.52%
14,169 $949,000
Q1 2024

May 15, 2024

SELL
$25.72 - $29.94 $82,818 - $96,406
-3,220 Reduced 5.68%
53,507 $1.45 Million
Q4 2023

Feb 14, 2024

SELL
$23.42 - $31.74 $60,072 - $81,413
-2,565 Reduced 4.33%
56,727 $1.76 Million
Q3 2023

Nov 14, 2023

SELL
$19.86 - $26.93 $1.05 Million - $1.43 Million
-53,000 Reduced 47.2%
59,292 $1.5 Million
Q2 2023

Aug 14, 2023

BUY
$16.44 - $21.1 $1.85 Million - $2.37 Million
112,292 New
112,292 $2.37 Billion
Q1 2023

May 15, 2023

BUY
$16.26 - $21.73 $578,660 - $773,327
35,588 Added 20.25%
211,340 $3.6 Million
Q4 2022

Feb 14, 2023

BUY
$16.98 - $23.15 $1 Million - $1.36 Million
58,908 Added 50.42%
175,752 $0
Q3 2022

Nov 14, 2022

SELL
$20.88 - $28.21 $668,160 - $902,720
-32,000 Reduced 21.5%
116,844 $2.52 Billion
Q2 2022

Aug 12, 2022

BUY
$17.07 - $25.71 $1.26 Million - $1.9 Million
73,844 Added 98.46%
148,844 $2.94 Million
Q1 2022

May 16, 2022

BUY
$20.42 - $28.13 $714,700 - $984,550
35,000 Added 87.5%
75,000 $1.76 Million
Q2 2019

Aug 14, 2019

SELL
$23.0 - $32.19 $985,734 - $1.38 Million
-42,858 Reduced 51.72%
40,000 $0
Q3 2017

Nov 14, 2017

BUY
$11.61 - $31.21 $961,981 - $2.59 Million
82,858
82,858 $0

Others Institutions Holding INSM

About INSMED Inc


  • Ticker INSM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 135,476,992
  • Market Cap $10.6B
  • Description
  • Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversibl...
More about INSM
Track This Portfolio

Track Ubs Oconnor LLC Portfolio

Follow Ubs Oconnor LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Oconnor LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Oconnor LLC with notifications on news.